Pharma and Life Sciences Investigations and Prosecutions: The First Two Years of the Biden Administration -

With the two-year mark of the Biden presidency looming, the administration’s approach to prosecuting and investigating entities and individuals in the life sciences industry has begun to present itself with greater clarity. The administration has relied more heavily upon certain civil actions and less heavily upon others as compared to its predecessor. And while prosecution figures have remained steady, the Department of Justice (DOJ) has, like other federal agencies, tailored its enforcement efforts to combatting COVID-19-related fraud while, at the same time, continuing its focus on healthcare fraud of all forms.